| Bid | 0.58 |
| Market Cap | 149.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -3.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.65 |
| Volume | 993,149 |
| Avg. Volume (20D) | 2,196,791 |
| Open | 0.64 |
| Previous Close | 0.60 |
| Day's Range | 0.58 - 0.64 |
| 52-Week Range | 0.53 - 2.05 |
| Beta | undefined |
About ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa...
Analyst Forecast
According to 4 analyst ratings, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is $3.15, which is an increase of 437.63% from the latest price.
Next Earnings Release
Analysts project revenue of $9.93M, reflecting a 4.20K% YoY growth and earnings per share of -0.16, making a -33.33% decrease YoY.
2 months ago · seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call TranscriptAdaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams...
2 months ago · newsfilecorp.com
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be ...
